Moderna Inc (NASDAQ:MRNA) shares are trading higher by 4.7% at $165.44 Thursday afternoon after a Japan health panel recommended approval of the company’s COVID-19 vaccine.
Moderna is engaged in creating transformative medicines based on messenger RNA, or mRNA. It transfers the information stored in the genes to the cellular machinery that makes all the proteins required for life.
